Dual inhibition of CSF-1R and IDO modulates the fibrotic and immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinoma - Scorecard - MDSpire

Dual inhibition of CSF-1R and IDO modulates the fibrotic and immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinoma

  • By

  • Lara C. Avsharian

  • Suvithanandhini Loganathan

  • Nancy D. Ebelt

  • Rebecca E. Ruggiero-Ruff

  • Sheyla Salcido

  • Skye E. Inal

  • Meera G. Nair

  • Edwin R. Manuel

  • July 15, 2026

Share

Clinical Scorecard: Combined Targeting of CSF-1R and IDO Alters the Fibrotic and Immunosuppressive Environment in Pancreatic Ductal Adenocarcinoma

At a Glance

CategoryDetail
ConditionPancreatic Ductal Adenocarcinoma (PDAC)
Key MechanismsCSF-1R signaling and TGF-β secretion contribute to fibrosis and immune suppression.
Target PopulationPatients with PDAC characterized by high fibrosis and CSF-1R expression.
Care SettingOncology research and clinical trials.

Key Highlights

  • PDAC is highly fibrotic and immunosuppressive, limiting therapeutic efficacy.
  • Dual targeting of CSF-1R and IDO significantly reduces tumor burden in high fibrosis models.
  • Therapeutic response to CSF-1R inhibition is context-dependent based on tumor fibrosis.
  • PMN-MDSC infiltration may limit the efficacy of CSF-1R inhibitor monotherapy.
  • Biomarkers of fibrosis and CSF-1R expression may guide immunotherapeutic strategies.

Guideline-Based Recommendations

Diagnosis

  • Evaluate tumor fibrosis and CSF-1R expression as potential biomarkers.

Management

  • Consider combined CSF-1R and IDO inhibition for patients with high fibrosis PDAC.

Monitoring & Follow-up

  • Assess intratumoral immune cell composition post-therapy.

Risks

  • Monitor for compensatory PMN-MDSC recruitment following CSF-1R inhibition.

Patient & Prescribing Data

Patients with advanced PDAC exhibiting high levels of fibrosis.

Combination therapy may enhance anti-tumor immunity and reduce fibrosis.

Clinical Best Practices

  • Utilize biomarker-guided approaches for immunotherapy in PDAC.
  • Monitor treatment response through changes in immune cell profiles.

Related Resources & Content

Original Source(s)

Dual inhibition of CSF-1R and IDO modulates the fibrotic and immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinoma

  • by Lara C. Avsharian, Suvithanandhini Loganathan, Nancy D. Ebelt, Rebecca E. Ruggiero-Ruff, Sheyla Salcido, Skye E. Inal, Meera G. Nair, Edwin R. Manuel

  • July 15, 2026

Related Content

Commentary: Post-translational modifications in retinoblastoma: mechanisms, immune regulation, and therapeutic opportunities

Emerging role of ETV4 in colorectal cancer: from molecular mechanisms to clinical implications

Editorial: The multifaceted role of cholangiocytes in neoplastic and non-neoplastic cholangiopathies: from bench to bedside